Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report

A. John Rush, Madhukar H. Trivedi, Stephen R. Wisniewski, Andrew A. Nierenberg, Jonathan W. Stewart, Diane Warden, George Niederehe, Michael E. Thase, Philip W. Lavori, Barry D. Lebowitz, Patrick J. McGrath, Jerrold F. Rosenbaum, Harold A. Sackeim, David J. Kupfer, James Luther, Maurizio Fava

Research output: Contribution to journalArticle

2333 Citations (Scopus)

Abstract

Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N= 3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR 16) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD17]) defined remission; a QIDS-SR16 total score of ≥11 (HRSD17≥14) defined relapse. Results: The QIDS-SR16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps. Conclusions: When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.

Original languageEnglish (US)
Pages (from-to)1905-1917
Number of pages13
JournalAmerican Journal of Psychiatry
Volume163
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Outpatients
Depression
Therapeutics
Recurrence
Major Depressive Disorder
Self Report
Equipment and Supplies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report. / Rush, A. John; Trivedi, Madhukar H.; Wisniewski, Stephen R.; Nierenberg, Andrew A.; Stewart, Jonathan W.; Warden, Diane; Niederehe, George; Thase, Michael E.; Lavori, Philip W.; Lebowitz, Barry D.; McGrath, Patrick J.; Rosenbaum, Jerrold F.; Sackeim, Harold A.; Kupfer, David J.; Luther, James; Fava, Maurizio.

In: American Journal of Psychiatry, Vol. 163, No. 11, 11.2006, p. 1905-1917.

Research output: Contribution to journalArticle

Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, Niederehe, G, Thase, ME, Lavori, PW, Lebowitz, BD, McGrath, PJ, Rosenbaum, JF, Sackeim, HA, Kupfer, DJ, Luther, J & Fava, M 2006, 'Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report', American Journal of Psychiatry, vol. 163, no. 11, pp. 1905-1917. https://doi.org/10.1176/appi.ajp.163.11.1905
Rush, A. John ; Trivedi, Madhukar H. ; Wisniewski, Stephen R. ; Nierenberg, Andrew A. ; Stewart, Jonathan W. ; Warden, Diane ; Niederehe, George ; Thase, Michael E. ; Lavori, Philip W. ; Lebowitz, Barry D. ; McGrath, Patrick J. ; Rosenbaum, Jerrold F. ; Sackeim, Harold A. ; Kupfer, David J. ; Luther, James ; Fava, Maurizio. / Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 11. pp. 1905-1917.
@article{98002aa6a5774807abdea0f697c02cf9,
title = "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report",
abstract = "Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N= 3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR 16) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD17]) defined remission; a QIDS-SR16 total score of ≥11 (HRSD17≥14) defined relapse. Results: The QIDS-SR16 remission rates were 36.8{\%}, 30.6{\%}, 13.7{\%}, and 13.0{\%} for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67{\%}. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps. Conclusions: When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.",
author = "Rush, {A. John} and Trivedi, {Madhukar H.} and Wisniewski, {Stephen R.} and Nierenberg, {Andrew A.} and Stewart, {Jonathan W.} and Diane Warden and George Niederehe and Thase, {Michael E.} and Lavori, {Philip W.} and Lebowitz, {Barry D.} and McGrath, {Patrick J.} and Rosenbaum, {Jerrold F.} and Sackeim, {Harold A.} and Kupfer, {David J.} and James Luther and Maurizio Fava",
year = "2006",
month = "11",
doi = "10.1176/appi.ajp.163.11.1905",
language = "English (US)",
volume = "163",
pages = "1905--1917",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "11",

}

TY - JOUR

T1 - Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps

T2 - A STAR*D report

AU - Rush, A. John

AU - Trivedi, Madhukar H.

AU - Wisniewski, Stephen R.

AU - Nierenberg, Andrew A.

AU - Stewart, Jonathan W.

AU - Warden, Diane

AU - Niederehe, George

AU - Thase, Michael E.

AU - Lavori, Philip W.

AU - Lebowitz, Barry D.

AU - McGrath, Patrick J.

AU - Rosenbaum, Jerrold F.

AU - Sackeim, Harold A.

AU - Kupfer, David J.

AU - Luther, James

AU - Fava, Maurizio

PY - 2006/11

Y1 - 2006/11

N2 - Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N= 3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR 16) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD17]) defined remission; a QIDS-SR16 total score of ≥11 (HRSD17≥14) defined relapse. Results: The QIDS-SR16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps. Conclusions: When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.

AB - Objective: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Method: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N= 3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of ≤5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR 16) (equivalent to ≤7 on the 17-item Hamilton Rating Scale for Depression [HRSD17]) defined remission; a QIDS-SR16 total score of ≥11 (HRSD17≥14) defined relapse. Results: The QIDS-SR16 remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps. Conclusions: When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.

UR - http://www.scopus.com/inward/record.url?scp=33751338530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751338530&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.163.11.1905

DO - 10.1176/appi.ajp.163.11.1905

M3 - Article

C2 - 17074942

AN - SCOPUS:33751338530

VL - 163

SP - 1905

EP - 1917

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 11

ER -